Skip to main content
. 2023 May 24;55(5):842–852. doi: 10.3724/abbs.2023049

Figure 1 .

Figure 1

EXO1 is highly expressed in patients with osteosarcoma (OS) and is associated with poor prognosis

(A) Heat map analysis of differentially expressed genes (DEGs) in the control vs G0-sorted OS cells (left) and in the control vs doxorubicin (DOX)-treated OS cells (right). (B) Venn diagram of DEGs. Gene list A indicates upregulated DEGs in normal vs quiescent OS; Gene list B indicates upregulated DEGs in normal vs senescent OS. (C) Node degree distribution of the 360 intersecting DEGs’ PPI network, including 112 nodes. (D) TCGA database analysis shows that high EXO1 expression is significantly associated with poor prognosis in OS patients. Overall survival (OS), P=0.015, groups for EXO1 high expression n=211; groups for EXO1 low expression n=239. Disease-free interval (DFI), P=0.011, groups for EXO1 high expression n=108; groups for EXO1 low expression n=132. Disease-specific survival (DSS), P=0.0062, groups for EXO1 high expression n=208; groups for EXO1 low expression n=229. Progression-free interval (PFI), P=0.037, groups for EXO1 high expression n=172; groups for EXO1 low expression n=200.